drugset / Trial / NCT00415103
AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this trial is to determinate the security, tolerability and efficacy of aprepitant plus palonosetron versus granisetron in the prevention of nausea and emesis induced by chemotherapy in patients treated with haematopoietic progenitors transplant.
Timeline
- Start
- 2006-11
- Primary completion
- 2009-09
- Completion
- 2009-09
Publications
- Background Bosi 1993; Agura 1995; Okamoto 1996
- Background MASCC Consensus Conference on Antihemetic Therapy, 2004)
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 80 mg | Oral |
| Comparator | Granisetron | Other / unclassified | 3 mg | Intravenous |
| Subject | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |